192 related articles for article (PubMed ID: 610314)
1. Hypogonadal men treated with oral testosterone undecanoate.
Sarris S; Swyer GI; Lawrence DM
Acta Eur Fertil; 1977 Dec; 8(4):297-9. PubMed ID: 610314
[TBL] [Abstract][Full Text] [Related]
2. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men.
Zhang GY; Gu YQ; Wang XH; Cui YG; Bremner WJ
J Androl; 1998; 19(6):761-8. PubMed ID: 9876028
[TBL] [Abstract][Full Text] [Related]
3. Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study.
von Eckardstein S; Nieschlag E
J Androl; 2002; 23(3):419-25. PubMed ID: 12002444
[TBL] [Abstract][Full Text] [Related]
4. A ten-year safety study of the oral androgen testosterone undecanoate.
Gooren LJ
J Androl; 1994; 15(3):212-5. PubMed ID: 7928661
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy of testosterone undecanoate in male hypogonadism.
Maisey NM; Bingham J; Marks V; English J; Chakraborty J
Clin Endocrinol (Oxf); 1981 Jun; 14(6):625-9. PubMed ID: 7296909
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84-week phase III clinical trial.
Wang C; Harnett M; Dobs AS; Swerdloff RS
J Androl; 2010; 31(5):457-65. PubMed ID: 20133964
[TBL] [Abstract][Full Text] [Related]
7. Plasma levels of dihydrotestosterone remain in the normal range in men treated with long-acting parenteral testosterone undecanoate.
Yassin AA; Saad F
Andrologia; 2007 Oct; 39(5):181-4. PubMed ID: 17714216
[TBL] [Abstract][Full Text] [Related]
8. Serum testosterone and bioavailable testosterone correlate with age and body size in hypogonadal men treated with testosterone undecanoate (1000 mg IM--Nebido).
Moisey R; Swinburne J; Orme S
Clin Endocrinol (Oxf); 2008 Oct; 69(4):642-7. PubMed ID: 18394021
[TBL] [Abstract][Full Text] [Related]
9. Testosterone undecanoate in the treatment of male hypogonadism.
Edelstein D; Basaria S
Expert Opin Pharmacother; 2010 Aug; 11(12):2095-106. PubMed ID: 20642374
[TBL] [Abstract][Full Text] [Related]
10. Serum adiponectin levels in hypogonadal males: influence of testosterone replacement therapy.
Lanfranco F; Zitzmann M; Simoni M; Nieschlag E
Clin Endocrinol (Oxf); 2004 Apr; 60(4):500-7. PubMed ID: 15049966
[TBL] [Abstract][Full Text] [Related]
11. [Scrotal testosterone patches: a good addition to therapeutic options for hypogonadal men].
Asscheman H; Gooren LJ
Ned Tijdschr Geneeskd; 2000 Apr; 144(18):847-50. PubMed ID: 10816775
[TBL] [Abstract][Full Text] [Related]
12. Long acting testosterone undecanoate therapy in men with hypogonadism: results of a pharmacokinetic clinical study.
Morgentaler A; Dobs AS; Kaufman JM; Miner MM; Shabsigh R; Swerdloff RS; Wang C
J Urol; 2008 Dec; 180(6):2307-13. PubMed ID: 18930255
[TBL] [Abstract][Full Text] [Related]
13. Testosterone undecanoate: a new orally active androgen.
Hirschhäuser C; Hopkinson CR; Sturm G; Coert A
Acta Endocrinol (Copenh); 1975 Sep; 80(1):179-87. PubMed ID: 1098350
[TBL] [Abstract][Full Text] [Related]
14. Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men.
Nieschlag E; Büchter D; Von Eckardstein S; Abshagen K; Simoni M; Behre HM
Clin Endocrinol (Oxf); 1999 Dec; 51(6):757-63. PubMed ID: 10619981
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men.
Grober ED; Khera M; Soni SD; Espinoza MG; Lipshultz LI
Int J Impot Res; 2008; 20(2):213-7. PubMed ID: 17898800
[TBL] [Abstract][Full Text] [Related]
16. Testosterone treatment comes of age: new options for hypogonadal men.
Nieschlag E
Clin Endocrinol (Oxf); 2006 Sep; 65(3):275-81. PubMed ID: 16918944
[TBL] [Abstract][Full Text] [Related]
17. Correlation between simultaneous PSA and serum testosterone concentrations among eugonadal, untreated hypogonadal and hypogonadal men receiving testosterone replacement therapy.
Grober ED; Lamb DJ; Khera M; Murthy L; Lipshultz LI
Int J Impot Res; 2008; 20(6):561-5. PubMed ID: 18843272
[TBL] [Abstract][Full Text] [Related]
18. Bone mineral density in hypogonadal men remains low after long-term testosterone replacement.
Ishizaka K; Suzuki M; Kageyama Y; Kihara K; Yoshida K
Asian J Androl; 2002 Jun; 4(2):117-21. PubMed ID: 12085102
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome.
Aversa A; Bruzziches R; Francomano D; Spera G; Lenzi A
J Endocrinol Invest; 2010 Dec; 33(11):776-83. PubMed ID: 20220293
[TBL] [Abstract][Full Text] [Related]
20. Timetable of effects of testosterone administration to hypogonadal men on variables of sex and mood.
Jockenhövel F; Minnemann T; Schubert M; Freude S; Hübler D; Schumann C; Christoph A; Gooren L; Ernst M
Aging Male; 2009 Dec; 12(4):113-8. PubMed ID: 19909203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]